Invitrogen™ Vaccinia Virus B18R (Carrier-Free) Recombinant Protein, eBioscience™

Recombinant Protein

Catalog Number	Mfr. No.	Quantity
34-818-586	Invitrogen™ 34818586	1mg
50-933-2	Invitrogen™ 34818585	500μg
50-245-764	Invitrogen™ 34818581	50μg

Description

The B18R protein is a vaccinia virus-encoded receptor with specificity for mouse, human, rabbit, pig, rat, and cow type I interferons which has potent neutralizing activity.B18R that acts as a decoy receptor for Type I Interferons (IFNa, IFNb, IFNe,k,t,d,z, w,v) . B18R was recently identified to enable increased cell viability during RNA transfection protocols designed to convert human somatic donor cells into iPSCs via direct delivery of modified synthetic mRNAs for OCT4, SOX2, KLF4 and MYC (OSKM) and Lin28 with the aim to enable highly efficient reprogramming of somatic cells to pluripotency. This allows for re-directed differentiation toward a desired lineage while removing the risk of genomic integration and insertional mutagenesis inherent to DNA-bases methodologies and eliminates the need for virus-based approaches. iPSCs represent a widely available, non-controversial and practically infinite source of pluripotent cells.The B18R protein is a type I interferon receptor encoded by the B18R gene of the Western Reserve vaccinia virus strain. The 60-65 kD glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN-receptors, which belong to the class II cytokine receptor family. The B18R protein has a high affinity (KD, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to type I interferons of human, mouse, rat, rabbit, pig, and cow. Among viral host response modifiers, the B18R protein is unique in that it exists as a soluble extracellular, as well as a cell surface protein, enabling blockage of both autocrine and paracrine IFN functions. The B18R protein has been shown to inhibit the antiviral potency of IFN-alpha1, IFN-alpha2 , IFN-alpha-8/1/8, and IFN-omega on human cells. The soluble B18R protein is highly potent for neutralizing type I interferons, which include IFN-alpha, beta, delta, kappa. Please note effects on mouse IFNs vary from other species; it has been shown that B18R does not neutralize mouse IFN beta. Description: TThe B18R protein is a vaccinia virus-encoded receptor with specificity for mouse, human, rabbit, pig, rat, and cow type I interferons which has potent neutralizing activity. B18R that acts as a decoy receptor for Type I Interferons (IFNa, IFNb, IFNe,k,t,d,z,w,v). B18R was recently identified to enable increased cell viability during RNA transfection protocols designed to convert human somatic donor cells into iPSCs via direct delivery of modified synthetic mRNAs for OCT4, SOX2, KLF4 and MYC (OSKM) and Lin28 with the aim to enable highly efficient reprogramming of somatic cells to pluripotency. This allows for re-directed differentiation toward a desired lineage while removing the risk of genomic integration and insertional mutagenesis inherent to DNA-bases methodologies and eliminates the need for virus-based approaches. iPSCs represent a widely available, non-controversial and practically infinite source of pluripotent cells. The B18R protein is a type I interferon receptor encoded by the B18R gene of the Western Reserve vaccinia virus strain. The 60-65 kD glycoprotein is related to the interleukin-1 receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN-receptors, which belong to the class II cytokine receptor family. The B18R protein has a high affinity (KD, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to type I interferons of human, mouse, rat, rabbit, pig, and cow. Among viral host response modifiers, the B18R protein is unique in that it exists as a soluble extracellular, as well as a cell surface protein, enabling blockage of both autocrine and paracrine IFN functions. The B18R protein has been shown to inhibit the antiviral potency of IFN-alpha1, IFN-alpha2 , IFN-alpha-8/1/8, and IFN-omega on human cells. The soluble B18R protein is highly potent for neutralizing type I interferons, which include IFN-alpha, beta, delta, kappa. Please note effects on mouse IFNs vary from other species; it has been shown that B18R does not neutralize mouse IFN beta. Applications Reported: Recombinant B18R is fully biologically active. Applications Tested: This recombinant B18R protein (type I IFN receptor) has been tested in bioassay for neutralization of mouse and human interferons ( alpha and beta). Human IFN: Pre-incubation of recombinant human IFN alpha2a with 0.1ug/mL B18R for 1 hr at RT was found to neutralize completely the activity of 1ng/mL IFN alpha2a. Mouse IFN: In an assay of EMCV infection of L929 cells, pre-incubation of recombinant mouse IFN alphaA with 250.0 picograms/mL B18R for 1 hr at RT was found to neutralize completely the activity of 5 pg/mL (1 Unit) mIFN alphaA. The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800 pg/mL in the presence of 1ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10e6 Units/mg. Source: Insect cells infected with baculovirus: amino acids His20-Glu 351 with a His-tag attached of Vaccinia Virus B18R accession &Num; D01019. Bioactivity: The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800 pg/mL in the presence of 1ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10e6 Units/mg. Endotoxin: Less than 0.01ng/ug cytokine as determined by the LAL assay. Purity: >98% as determined by SDS-PAGE. Molecular Weight: The polypeptide has a predicted molecular mass of 38,389. The DTT-reduced protein migrates as a 48 kDa polypeptide on SDS-PAGE due to glycosylation. The non-reduced protein migrates as a 46 kDa polypeptide on SDS-PAGE due to internal cystines. Storage and handling: For best recovery, quick-spin vial prior to opening. Use in a sterile environment.

Specifications

• Concentration: 0.5mg/mL
• Formulation: PBS with no preservative; pH 7.5
• Name: Vaccinia Virus B18R Carrier-Free
• Purification Method: SDS-PAGE
• Storage Requirements: -80°C
• Structural Form: Insect cells infected with baculovirus: amino acids His20-Glu 351 with a His-tag attached of Vaccinia Virus B18R accession # D01019
• Common Name: Vaccinia Virus B18R Carrier-Free
• Biological Activity: The ND50 of this protein, as measured by neutralization of Mouse IFN alpha 2 Recombinant Protein, is less than or equal to 800pg/mL in the presence of 1ng/mL Mouse IFN alpha 2. This corresponds to a specific activity of greater than or equal to 1.3 x 10⁶ Units/mg.
• Specific Reactivity: Bovine, Human, Mouse, Porcine, Rabbit, Rat
• Cross Reactivity: Bv, Hu, Ms, Po, Rb, Rt
• Recombinant: Recombinant
• Protein Subtype: Recombinant

• For Use With (Application): Control, Functional Assay
• Molecular Weight (g/mol): The polypeptide has a predicted molecular mass of 38,389. The DTT-reduced protein migrates as a 48kDa polypeptide on SDS-PAGE due to glycosylation. The non-reduced protein migrates as a 46kDa polypeptide on SDS-PAGE due to internal cystines.
• pH Range: 7.5
• Source: Vaccinia Virus
• Regulatory Status: RUO
• Endotoxin Concentration: Less than 0.01ng/μg cytokine as determined by the LAL assay.
• Gene Symbol: Vaccinia Virus-Encoded Neutralizing Type I Interferon Receptor; Type I IFN inhibitor
• Product Type: Recombinant Protein, Carrier-Free
• Conjugate: Unconjugated
• Species: Vaccinia virus
• Form: Liquid
• Purity or Quality Grade: Affinity chromatography

Safety and Handling

ShelfLife : 12 Months